Structure of the CR3 I domain in complex with C3d 2 Complement receptors (CR), expressed notably on myeloid and lymphoid cells, play an essential function in the elimination of complement-opsonized pathogens and apoptotic/necrotic cells. In addition, these receptors are crucial for the cross-talk between the innate and adaptive branches of the immune system. CR3 (also known as Mac-1, integrin  M  2 , or CD11b/CD18) is expressed on all macrophages and recognizes iC3b on complement-opsonized objects, enabling their phagocytosis. We demonstrate that the C3d moiety of iC3b harbours the binding site for the CR3 I domain, and our structure of the C3d:I domain complex rationalizes the CR3 selectivity for iC3b. Based on extensive structural analysis, we suggest that the choice between a ligand glutamate or aspartate for coordination of a receptor MIDAS-bound metal ion is governed by the secondary structure of the ligand. Comparison of our structure to the CR2:C3d complex and the in vitro formation of a stable CR3:C3d:CR2 complex suggests a molecular mechanism for the hand-over of CR3-bound immune complexes from macrophages to
conformation structure of the I domain ( Fig S4B) . The I domain α7 helix is shifted towards its C-terminus, and this conformation is most likely favoured by the I316G mutation introduced for this purpose. The open conformation is likewise adopted in the MIDAS site, where the hexa-coordinated metal ion is coordinated by Ser142, Ser144, Thr209 and two water molecules ( Fig. 2B) , whereas the last coordination position is occupied by an aspartate from C3d. As Mg 2+ was not compatible with the electron density in the MIDAS site, and since Ni 2+ was present in the crystallization buffer, we used anomalous diffraction data to confirm the presence of a Ni 2+ ion in the MIDAS site ( Fig. 2B and Table S1 ). The ability of Ni 2+ to stabilize MIDAS interactions with a ligand is well known from the complement convertases (18) .
Within the complex, C3d adopts the well-described compact α-α6 barrel structure ( Fig. 2A and Fig S4C) with only minor conformational differences compared to known structures containing C3d (19) (20) (21) . The -helix connecting loop regions of C3d are presented in an alternating fashion at the circumference of two opposite surfaces: a concave, mainly negatively charged surface, and a positively charged convex surface. At the rim of the concave surface Asp1247, situated in a loop region connecting helices 10 and 11 ( Fig. 2C and Fig S4C-D) , provides the final coordination bond to the divalent cation in the CR3 MIDAS ( Fig 2B) . The quite polar interface between C3d and the I domain is modest, with an area of approximately 490 Å 2 , which is smaller but comparable with similar I domain:ligand complexes (Table S2 ). Besides Asp1247 on C3d involved in the MIDAS ion interaction, the nearby Asp1245 in C3d engages in a salt bridge with CR3 Arg208 (Fig. 2C and Fig. S4D ).
C3d Lys1217 also seems to stabilize the interaction, as it is capable of forming salt bridges with CR3 Glu178 and Glu179 and hydrogen bonds with main chain carbonyls of Leu205 and Leu206. Finally, C3d Arg1254 also contributes to the interaction by forming hydrogen bonds with main-chain carbonyls of Gly143 and Ile145 in the I domain via a water molecule.
Conserved features of MIDAS-dependent ligand interactions. Besides iC3b, the CR3 I domain is responsible for interacting with a variety of ligands, including fibrinogen, ICAM-1 and RAGE (22) , but structures of their I domain complexes are not available. To identify general features among ligand side chains engaging in MIDAS ion coordination that might promote the identification of I domain interacting residues in other CR3 ligands, we identified all unique structures containing a Von Willebrand factor A domain or a βI domain engaging in a MIDAS-dependent interaction with a ligand protein. Comparison of these structures revealed obvious trends for the use of either aspartate or the longer glutamate side chains as MIDAS ligands. If the small aspartate side chain is used, as in the C3d complex, it is located in a loop region or at the termini of a peptide ( Fig. S5A-D) . This is even true for complexes between antibody Fab fragments and I domains ( Fig. S5E-G) , where an aspartate is located peripherally in the heavy chain CDR3 loop. Even smaller than the aspartate and located at the end of a flexible region is the exposed C-terminal carboxylate group in the non-catalytic subunit of complement convertases (C3b/cobra venom factor/C4b) coordinating the MIDAS ion in the VWA domain ( Fig. S5H ) of the catalytic subunit (factor B/C2). We found three unique examples involving the longer glutamate side chain ( Fig. S5I-K) . In complexes between the LFA-1 I domain and ICAM-1/3/5, a glutamate side chain at the end of a β-strand in an ICAM Ig-domain is a MIDAS ion ligand. A resembling situation is found for the α 2 β 1 I domain:collagen complex. In both cases the glutamate is protruding from a region containing regular secondary structure with little curvature and flexibility that would permit a closer approach to the MIDAS ion and the use of the shorter aspartate. In a third case, a crystal packing interaction by a glutamate located immediately after an α-helix mimics a ligand of the CR3 I domain (15) . Overall, there appears to be a steric selectivity in the MIDAS-ion coordination by ligand acidic groups: an aspartate side chain is preferred in loops or flexible termini, the longer glutamate is preferred in regions with secondary structure, whereas both aspartate and glutamate located next to secondary structure are possible MIDAS ion coordinators.
C3d Asp1247 is essential for CR3 I domain interaction. As integrins may promiscuously bind acidic residues exposed on protein surfaces (15, 16, 22) and to exclude crystal-packing artefacts, we mutated C3d residues in the intermolecular interface. We tested iC3b and wildtype (WT) or mutated C3d for their ability to interact with CR3 I domain by isothermal titration calorimetry (ITC) experiments ( Fig. 3 ). All the binding ligands interacted with the CR3 I domain in a 1:1 stoichiometry, and iC3b generated from C3b with factor I bound the I domain with a K D of 600 nM. The I domain bound WT C3d with a K D of 450 nM. These numbers are in good agreement with the high-affinity site identified by SPR ( Fig. 1B suggesting a crucial role of this aspartate in the interaction with the MIDAS-coordinated cation. Replacing Asp1247 by a glutamate also impaired the interaction showing that simple conservation of charge is not sufficient (Fig. 3 ). Most likely, when the longer glutamate side chain in this C3d mutant interacts with the I domain MIDAS site the adjoining interactions in the interface are difficult to form. The R1254A mutant ( Fig. 3 ) displayed a lowered affinity of 2.2 μM whereas the mutant C3d proteins K1217A and K1217A/ R1254A showed no detectable binding. Together, these data indicate that C3d Asp1247 is essential for the interaction with CR3 I domain, but is not sufficient, as other residues of the opposite charge, namely K1217 and R1254, are required to steer the interaction.
The physiological significance of the C3d:I domain structure. The in vitro confirmation of our crystal structure by ITC and SPR experiments is also supported by prior data, since the iC3b binding site on the CR3 I domain earlier suggested (23) is in excellent agreement with our structure. Furthermore, the participating residues are strictly or highly conserved in mammalian C3 and CR3  M sequences (Fig. S6A ). In contrast, none of the C3 residues involved in the I domain interaction are conserved in the structural C3 homologue C4 ( Fig.   S6B ) (24) , also being cleaved to C4b and undergoing further degradation to iC4b and C4d.
Likewise,  M residues with side chains interacting with C3d (Arg208, Glu178 and Glu179) are not conserved in CR4. Importantly, our structure also offers an explanation for why the iC3b proteolytic stage must be reached to allow CR3 interaction (25). The CUB domain in C3b connects the TE domain to the C3c moiety of C3b, and proteolytic degradation of the CUB domain probably causes its partial collapse in the resulting iC3b ( Fig. S1E ).
Superposition of known structures of C3b suggests that the CUB domain prevents the I domain from interacting with the TE domain by steric hindrance (Fig. 4 ). Finally, our structure is in accordance with a favourable geometry where the CR3 binding site of iC3b or C3d(g) opsonizing the activator is accessible for a phagocytotic CR3-presenting cell. The CR3 binding site is separated by 40 Å from the Gln1013 forming the covalent bond to the complement activator surface (Fig. 4A ). In conclusion, the in vivo relevance of our structure is strongly supported by 1) SPR and ITC experiments quantitating the interaction of iC3b, WT C3d and mutated C3d with the I domain, 2) the conservation of the residues in the molecular interface, 3) our ability to rationalize the discrimination against CR3 binding to C3b, and 4) the inferred lack of steric hindrance imposed by the activator upon CR3 binding.
The C3 thioester domain as a molecular hub. Our structure of the C3d:I domain complex together with the structures of C3 (26, 27), the C3d complexes with factor H (20, 28) and CR2 (21) demonstrate that a substantial fraction of the surface of the C3 TE domain is involved in intra-or inter-molecular contacts in one of the multiple functional states of C3. Strikingly, surface residues on the TE domain interacting with other domains in native C3 are almost perfectly separated from those surface patches forming contacts with fH, CR3 and CR2 in their C3d complexes. In C3, the convex surface of C3d forms contacts with the MG2, CUB and MG8 domains (total interface area of ~2650 Å 2 ) that bury more than 20% of the TE domain surface (Fig. 5A ). On the circumference and the rim of the concave surface of C3d, surface patches interacting with fH (~600 Å 2 ), CR3 (~500 Å 2 ), and CR2 (~1100 Å 2 ) are likewise almost perfectly non-overlapping with each other and with the above-mentioned C3 inter-domain interface ( Fig. 5B-C ). Hence, especially in the iC3b state, the TE domain may bind simultaneously and strongly to the two complement receptors and collateral binding of factor H and CR3 appears possible as well.
Simultaneous binding of CR2 and CR3 to iC3b. Complement receptor 2 (CR2) binds with similar affinity to iC3b and C3d(g) and with C3d as the minimal ligand (29). To verify whether the formation of the CR2:C3d:CR3 complex suggested above is possible, C3d and CR2 CCP 1-2 were subjected to pull-down experiments with immobilized CR3 I domain.
Bound proteins were eluted with EDTA to disrupt MIDAS-ligand interactions. In the presence of WT C3d, both CR2 and C3d were eluted from the CR3 affinity column demonstrating that the CR3 I domain and CR2 CCP 1-2 are able to simultaneously bind to C3d ( Fig. 5D and Fig. S7 ). Using instead the C3d D1247A mutant no protein was eluted showing that CR2 is not interacting non-specifically with the resin and that this C3d aspartate is essential for interaction with the CR3 MIDAS. With the C3d mutant D1154A unable to bind CR2 (30), CR2 virtually absent from the EDTA eluate ( Fig. 5D and Fig. S7 ). To further corroborate the existence of the ternary CR2:C3d:CR3 complex, size exclusion chromatography experiments were conducted (Fig. S8 ). The chromatograms and SDS-PAGE analysis of fractions from these experiments showed that the complexes elute in the expected order CR3:C3d:CR2, CR3:C3d, CR2:C3d ( Fig. 5E and Fig. S8 ). Importantly, the presence of CR2 in the early fractions from the CR3:C3d:CR2 experiment can only be explained by the fact that CR2 was engaged in the ternary complex together with C3d and CR3. In conclusion, our pull-down and size exclusion chromatography experiments confirmed the existence of a ternary complex in which the CR3 I domain and the CR2 CCP 1-2 fragment bind simultaneously to C3d.
Discussion
The engulfment by immune cells of complement-opsonized objects is a fundamental property of the human immune defence where CR3 plays an essential role (8) . CR3's specificity for iC3b as ligand has been established for thirty years. Now, our results define where and how CR3 interacts with iC3b and further emphasize the astonishing central role of the C3d moiety in intermolecular contacts. The CR3 I domain is well established as the primary binding site for iC3b (3, 31) . The quantitative findings in our study clearly suggest that the binding of the CR3 I domain to C3d is 100-500 fold stronger than its weaker binding of simple acidic groups. Hence, the structure of the C3d:CR3 I domain complex portraits a type of interaction distinct from the earlier report showing the binding to a ligand mimetic, i.e., glutamate side chain contributed by a crystal lattice contact (15) . Nevertheless, while the I domain is an important determinant in the binding of iC3b and C3d(g), other regions in CR3 must contribute, since deletion of its I domain results in residual iC3b affinity (32). Both the  M propeller and the  2 I-like domain ( Fig. 4A ) have been suggested to be implicated in the interaction with iC3b (33-35). On the iC3b side, mutations in the Nt-' region weaken the iC3b-CR3 interaction (36). The degradation product C3d(g) is not normally considered as a CR3 ligand and soluble C3d cannot outcompete erythrocyte-bound iC3b in a rosette assay (37, 38). On the other hand, coating of erythrocytes with C3d facilitates their phagocytosis by monocytes in a metal ion-and CR3-dependent manner although C3d does this much less efficiently than iC3b (39). This is likely to directly mirror the interaction we observe in the crystal structure and have quantitated by SPR and ITC. In summary, there appears to be at least two contact points between iC3b and CR3 with a crucial one involving the C3d:I domain interaction established by us. If the iC3b Nt-'region in the C3c moiety of iC3b and the  M -propeller and the  2 I-like domain in CR3 indeed are important for the receptor-ligand interactions, contacts involving these are likely to be spatially well separated from the C3d:I domain interface (Fig. 4A ). Our model of iC3b binding to CR3 is clearly distinct from that proposed for CR4 by prior EM studies (13) . In side-by-side SPR experiments of the I domain binding of C3 fragments, the iC3b and C3d(g) fragments presented high-affinity binding sites for the CR3 I domain, while C3b and C3c had no such interactions. These findings corroborate earlier studies on the intact receptor supporting the relevance of studying the I domain selectivity towards C3 fragments. The CR4 I domain bound with almost indiscriminate kinetics to C3b, iC3b, and C3c, while the C3d(g) fragments were much poorer ligands. This is also in close agreement with the work by Chen et al. on the intact ectodomain of CR4, which identified a major binding site for this receptor involving the MG3 and MG4 domains of C3c (13) . The orientation of these domains, and hence the binding interface for CR4, are conserved between C3b and C3c (40), likely also making this the case for iC3b. This is quantitatively supported by the near-identical kinetics for the CR4 I domain binding of these fragments observed in our study.
Our finding that CR2 and the CR3 I domain can bind to the same molecule of C3d is intriguing, and since CR2 does not seem to recognize elements outside the C3d moiety of iC3b, our results imply that one iC3b or C3d(g) molecule on soluble immune complexes can bridge a CR3-presenting cell with a CR2-presenting cell. The location of the ligand-binding region (CR2 CCP 1-2 and CR3 I domain) at the distant end of these large receptors far from the cell membrane makes immune complex bridging between two cells a realistic scenario.
One important example is the suggested hand-over of complement-opsonized immune complexes from CR3-bearing subcapsular sinus macrophages to CR2 on naïve B cells or follicular dendritic cells in lymph nodes (10, 12) . Concerning the remaining complement receptors, the binding site for CR4 at the MG3-MG4 domains mapped by EM (13) seems not to overlap with regions implicated in binding CR3. Both receptors are expressed together on many cell types including macrophages, monocytes, neutrophils and NK cells (2) suggesting that simultaneous CR3 and CR4 binding to the same iC3b molecule is possible. The CRIg receptor expressed on a subset of tissue macrophages recognizes C3b, iC3b and C3c, and its binding site has been mapped to the MG domains 3, 4, 5, 6 and the LNK regions of C3b (41).
As the structure of iC3b is only known to low resolution and controversial (13) , the exact spatial relation between the iC3b binding sites for CRIg and the CR3 I domain found by us is unknown but likely to be variable. However, these sites are non-overlapping suggesting that both receptors could bind simultaneously to iC3b unless other parts of CR3 compete with CRIg. With respect to complement receptor 1, both CR1 and CR3 binding involve the same part of the Nt-α′ region (36) suggesting mutually exclusive binding of the two receptors to the same iC3b molecule.
Therapeutic intervention through blockade of CR3 has been suggested for treatment of cerebral stroke (42). Furthermore, macrophage migration to the brain is likely to involve CR3 (43). However, due to the diversity of CR3 ligands, its central role in immune clearance of pathogens and apoptotic cells by phagocytosis (8, 44) , adhesion (45, 46), and transmigration (47) overall or even function specific CR3 blockade is not without risks. As an example, systemic lupus erythematosus is tightly linked with a single mutation in the α M chain of CR3, that mainly affects its role in phagocytosis (48). In the same manner, C3b and its proteolytic fragments also engage in interactions with a large number of other proteins thereby severely complicating the development of complement inhibitors. Our structure of the C3d:I domain complex provides an important contribution to the development of more selective complement inhibitors by identifying the surface areas on the CR3 I domain and on the C3d moiety of importance for their mutual interaction. Due to the proximity of the C3d-CR2 interaction it may also contribute to improve the CR2-based targeting strategies under development for site-specific delivery of complement inhibitors (49). 
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EXPERIMENTAL PROCEDURES
Protein expression and purification. C3 proteolytic fragments were generated according to (1, 2) with minor modifications. The human CR3 I domain (subunit  M residues 127-321) mutant C128S/I316G was subcloned into pETM-11. A codon-optimized C3d gene (encoding protein residues 993-1288 of human C3, mutant C1010A, GenScript USA, Inc) was subcloned into pETM-20. Both proteins were expressed in BL21 (DE3) E. coli cells. Cells harbouring the recombinant plasmid were grown at 37 °C in 2xTY medium where protein expression was induced at OD 600 ≈0.6 Surface plasmon resonance spectroscopy and data analysis were carried out essentially as described earlier (4) using a BIAcore 3000 instrument (GE Healthcare) to examine the binding of the CR3and CR4 I domains to proteolytic C3 fragments. C3b, iC3b, C3c, C3dg and C3d were coupled through primary amine groups to CM4 sensor chips. A reference flow-cell was prepared by coupling of ethanolamine. CR3 or CR4 I domain in concentrations ranging from 250 nM to 100 μM, diluted in 10 mM HEPES pH 7.5, 150 mM NaCl, 1 mM MgCl 2, , was injected at a flow rate of 10 μl/min over the sensor chips with a contact time of 250 s, followed by a dissociation phase of 150 s. The sensor chips were regenerated in 100 mM HEPES pH 7.5, 1.5 M NaCl, 50 mM EDTA. Following subtraction of the reference cell signal, the distribution of interactions was calculated from the resulting sensorgram using the EVILFIT algorithm (5, 6) as described earlier (4, 7).
Pull-down assay. A CR3 I domain affinity column was generated by coupling 4 mg of purified
CR3 I domain to 600 μl of CNBr-activated Sepharose. C3d was added in the binding buffer (50 mM HEPES pH 7.5, 150 mM NaCl, 10 mM MgCl 2 ) and the column was washed with 10 columnvolume wash steps using the same buffer. After that CR2 CCP 1-2 was added in the binding buffer and the wash procedure repeated. Elution was carried out with 50 mM HEPES pH 7.5, 1 M NaCl, 50 mM EDTA. C3d D1247A and C3d D1154A mutants, defective in binding of CR3 and CR2 respectively, were used as controls. All the volumes in wash and elution steps were exactly the same. Likewise, the volumes loaded on the SDS-PAGE ( Fig. 5D and Fig S7) were identical.
Size exclusion chromatography.
This was performed on a 5 ml analytical column (Agilent Bio dimethyloctylphosphine oxide). Prior to data collection, the crystals were cryoprotected in mother liquor containing additional 30% glycerol and flash-frozen in liquid nitrogen. Native data were collected at 0.9 Å with a rotation of 0.1° per image on the PX1 beamline, SLS Villigen. Anomalous diffraction data were collected at 1.45 Å with a rotation of 0.5° per image on the ID23-1 beamline, ESRF Grenoble. Data reduction was carried out with XDS (9) (Table S1).
Structure determination and analysis. The structure was solved with molecular replacement in PHASER (10) using the CR3 I domain (RCSB entry 1IDO) and C3d (RCSB entry 1C3D) as search models. Rebuilding with Coot (11) and refinement with phenix.refine (12) were carried out in an iterative manner, while model quality was assessed with MolProbity (13) . Buried surface area calculation was done with PISA or CNS (14, 15) . All figures were prepared with the PyMOL Molecular Graphics System v1.5.0.4, Schrödinger LLC. . This can be explained by the fact that their theoretical hydrodynamic radii are similar (1.82 nm for C3d and 2.09 nm for CR2:C3d). The CR3:C3d complex elutes as a double peak (panel E) suggesting that association/dissociation equilibrium is taking place, consistent with very fast on and off rates observed in our SPR analyses. Finally, the ternary CR2:C3d:CR3 complex elutes also as a double peak but slightly earlier than the binary CR3:C3d complex (panel F). The very close elution volumes can be explained by very similar hydrodynamic radii of 2.74 and 2.77 nm for the CR3:C3d and the CR2:C3d:CR3 complex respectively.
Legends to Figures S1-S8
Legends to Table S2
Table S2. Interface properties of complexes between I domains and ligands. The interface areas and the P-values were calculated with PISA (15) . For protein-protein interfaces P-value<0.5 means that the interface is more hydrophobic than could be expected if surface atoms were picked randomly, and P>0.5 means that the interface is more hydrophilic than could be expected. The I domain:ligand interfaces are dominated by the electrostatic interaction between the ligand aspartate/glutamate and the MIDAS ion, however, the P-values calculated from these complexes are not directly comparable to protein-protein interfaces devoid of such an interaction. The shape complementarity was calculated with the CCP4 program SC (28). Ni 2+ 
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